LA
LGND icon

Lee Ainslie’s Ligand Pharmaceuticals LGND Stock Holding History

Lee Ainslie’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-26,432
Closed -$1.72M – 511
2019
Q4 		$1.72M Buy
+26,432
New +$1.77M 0.03% 282

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return

Lee Ainslie's LGND Position: Q1 2020 in Review

Lee Ainslie sold out of Ligand Pharmaceuticals (LGND) in Q1 2020, closing a stake of 26,432 shares — an estimated $1.72M sold.

Lee Ainslie first reported a position in LGND in Q4 2019 and held it in 1 quarter. The position peaked at $1.72M in Q4 2019. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

  • Lee Ainslie reported no remaining Ligand Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Lee Ainslie sold 26,432 Ligand Pharmaceuticals shares in Q1 2020, an estimated $1.72M.
  • Lee Ainslie first reported a position in Ligand Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Lee Ainslie's Ligand Pharmaceuticals position peaked at $1.72M in Q4 2019.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Maverick Capital's 13F filing for Q1 2020, filed 15 May 2020.